15-Deoxyspergualin inhibits interleukin 6 production in in vitro stimulated human lymphocytes

Transplant Immunology

Volumn 4, Issue 2, 1996, Pages 133-143

  Johansson Borg, Anette ^a   Kumagai Braesch, Makiko ^a   Möller, Erna ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; CONCANAVALIN A; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHYTOHEMAGGLUTININ; RECOMBINANT INTERLEUKIN 6; SUPERANTIGEN; TACROLIMUS;

ANTIBODY PRODUCING CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOBLAST; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0030175157     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(96)80007-4     Document Type: Article

References (57)

1. Takeuchi T, Iinuma H, Kunimoto S, et al. A new antitumour antibiotic, spergualin: isolation and antitumor activity. J Antibiot. 34:1981;1619-1621.
2. Umeda Y, Moriguchi M, Kuroda H, et al. Synthesis and antitumor activity of spergualin analogues I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety. J Antibiot. 38:1985;886-898.
3. Dickneite G, Schorlemmer H.U, Walter P, Thies J, Sedlacek H.H. The influence of (±)-15-deoxyspergualin on experimental transplantation and its immunopharmacological mode of action. Behring Inst Mitt. 80:1986;93-102.
4. Dickneite G, Schorlemmer H.U, Weinmann E, Barlett R.R, Sedlacek H.H. Skin transplantation in rats and monkeys: evaluation of efficient treatment with 15-deoxyspergualin. Transplant Proc. 19:1987;4244-4247.
5. Engemann R, Gassel H.J, Lafrenz E, Stoffregen C, Thiede A, Hammelmann H. The use of 15-deoxyspergualin in orthotopic rat liver transplantation: induction of transplantation tolerance and treatment of acute rejection. Transplant Proc. 20:1988;237-239. (1, suppl. 1).
6. Corry R.J, Cutkomp J, Oberholser J.H, Kapelanski D.P, Wakely E. Prolongation of allograft and xenograft survival with 15-deoxyspergualin. Transplant Proc. 21:1989;530-531.
7. Ochiai T, Hori S, Nakajima K, Nagata M, Asano T, Isono K. Prolongation of rat heart allograft survival by 15-deoxyspergualin. J Antibiot. 40:1987;249-250.
8. Nemoto K, Hayashi M, Ito J, et al. Deoxspergualin in lethal murine graft-versus-host disease. Transplantation. 51:1991;712-715.
9. Schubert G, Stoffregen C, Timmermann W, Schang T, Thiede A. Comparison of the new immunosuppressive agent 15-deoxyspergualin and cyclosporine A after highly allogeneic pancreas transplantation. Transplant Proc. 19:1987;3987-3997.
10. Ochiai T, Nakajima K, Sakamoto K, et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. Transplant Proc. 21:1989;829-832.
11. Fujii H, Takada T, Nemoto K, Abe F, Fujii A, Takeuchi T. In vitro immunosuppressive properties of spergualins to murine T cell response. J Antibiot. 42:1989;788-794.
12. Fujii H, Takada T, Nemoto K, et al. Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro. Int J Immunopharmacol. 14:1992;731-737.
13. Nishimura K, Tokunaga T. Mechanism of action of 15-deoxyspergualin. I. Suppressive effect on the induction of alloreactive secondary cytotoxic T lymphocytes in vivo and in vitro. Immunology. 68:1989;66-71.
14. Kerr P.G, Atkins R.C. Deoxyspergualin inhibits cytotoxic T lymphocytes but not NK or LAK cells. Immunol Cell Biol. 69:1991;177-183.
15. Takahara S, Jiang H, Takano Y, et al. The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. Transplantation. 53:1992;914-918.
16. Tepper M.A, Nadler S, Mazzucco C, Singh C, Kelley S.L. 15-Deoxyspergualin, a novel immunosuppressive drug: studies of the mechanism of action. Ann NY Acad Sci. 685:1993;136-147.
17. Ito S, Ueno M, Arakawa M, Saito T, Aoyagi T, Fujiwara M. Therapeutic effect of 15-deoxyspergualin on the progression of lupus nephritis in MRL mice. I. Immunopathological analyses. Clin Exp Immunol. 81:1990;446-453.
18. Makino M, Fujiwara M, Watanabe H, Aoyagi T, Umezawa H. Immunosuppressive activities of deoxyspergualin. II. The effect on the antibody responses. Immunopharmacology. 14:1987;115-122.
19. Morikawa K, Oseko F, Morikawa S. The suppressive effect of deoxyspergualin on the differentiation of human B lymphocytes maturing into immunoglobulin-producing cells. Transplantation. 54:1992;526-531.
20. Valdivia L.A, Monden M, Gotoh M, Nakano Y, Tono T, Mori T. Evidence that deoxyspergualin prevents sensitization and first-set cardiac xenograft rejection in rats by suppression of antibody formation. Transplantation. 50:1990;132-136.
21. Yuh D.D, Morris R.E. The immunopharmacology of immunosuppression by 15-deoxyspergualin. Transplantation. 55:1993;578-591.
22. Yoshikawa Y, Uchida H, Kuroda H, et al. In vivo effects of deoxyspergualin (NKT-01) on lymphocyte activation in response to alloantigens. J Antibiot. 41:1988;1675-1680.
23. Takai Y, Wong G.G, Clark S.C, Burakoff S.J, Herrmann S.H. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol. 140:1988;508-512.
24. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 141:1988;1543-1549.
25. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 167:1988;332-344.
26. Brieva J.A, Martin R.A, Martinez-Maza O, et al. Interleukin 6 is essential for antibody secretion by human in vivo antigen-induced lymphoblastoid B cells. Cell Immunol. 130:1990;303-310.
27. Ruuskanen O III, Miller K, Pierce G, Sorensen R.U, Polmar S.H. Staphylococcus aureus Cowan I-induced immunoglobulin production in human cord blood lymphocytes. J Immunol. 125:1980;411-413.
28. Schuurman R.K.B, Gelfand E.W, Dosch A.-M. Polyclonal activation of human lymphocytes in vitro. I. Characterization of the lymphocytes response to a T cell-independent B cell mitogen. J Immunol. 125:1980;820-826.
29. Fleischer B. Superantigens. APMIS. 102:1994;3-12.
30. Leca G, Boumsell L, Fabbi M, Reinherz E.L, Kanellopoulos J.M. The sheep erythrocyte receptor and both α and β chains of the human T-lymphocyte antigen receptor bind the mitogenic lectin (phytohaemagglutinin) from Phaseolus vulgaris. Scand J Immunol. 23:1986;535-544.
31. Kanellopoulos J.M, Petris S.D, Leca G, Crumpton M.J. The mitogenic lectin from Phaseolus vulgaris does not recognise the T3 antigen of human T lymphocytes. Eur J Immunol. 15:1985;479-486.
32. O'Flynn K, Krensky A.M, Beverley P.C.L, Burakoff S.J, Linch D.C. Phytohaemagglutinin activation of T cells through the sheep redblood receptor. Nature. 313:1985;686-687.
33. Farrar M.A, Schreiber R.D. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol. 11:1993;571-611.
34. Yoshihara R, Shiozawa S, Fujita T, Chihara K. Gamma interferon is produced by human natural killer cells but not T cells during Staphylococcus aureus stimulation. Infect Immun. 61:1993;3117-3122.
35. Horii Y, Muraguchi A, Suematsu S, et al. Regulation of BSF-2/I1-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/Il-6 by T cells. J Immunol. 141:1988;1529-1535.
36. Hirata Y, Taga T, Hibi M, Nakano N, Hirano T, Kishimoto T. Characterization of Il-6 receptor expression by monoclonal and polyclonal antibodies. J Immunol. 143:1989;2900-2906.
37. Kuramochi H, Hiratsuka M, Nagamine S, et al. The antiproliferative action of deoxyspergualin is different from that induced by amine oxidase. J Antibiot. 41:1988;234-238.
38. Fujii H, Takada T, Nemoto K, Abe F, Takeuchi T. Stability and immunosuppressive activity of deoxyspergualin in comparison with deoxymethylspergualin. Transplant Proc. 21:1989;3471-3474.
39. Kerr P.G, Nikoloc-Paterson D.J, Lan H.Y, Tesch G, Rainone S, Atkins R.C. Deoxyspergualin suppresses local macrophage proliferation in rat renal allograft rejection. Transplantation. 58:1994;596-601.
40. Andersson U, Matsuda T. Human interleukin 6 and tumor necrosis factor α production studied at a single-cell level. Eur J Immunol. 19:1989;1157-1160.
41. Hoeger P.H, Tepper M.A, Faith A, Higgins J.A, Lamb J.R, Geha R.S. Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J Immunol. 153:1994;3908-3916.
42. Gallon L, Atshinger B, Murphy B, Akalin E, Sayegh M.H, Carpenter C.B. The indirect pathway of allorecognition. The occurrence of self-restricted T cell recognition of allo-MHC peptides early in acute renal allograft rejection and its inhibition by conventional immunosuppression. Transplantation. 59:1995;612-616.
43. Ulich T.R, Castillo J.D, Guo K. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating members of RBCs and WBCs. Blood. 73:1989;108-110.
44. Ikebuchi K, Wong G.G, Clark S.C, Ihle J.N, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA. 84:1987;9035-9039.
45. Ishibashi T, Kimura H, Shikama Y, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 74:1989;1241-1244.
46. Ishibashi T, Kimura H, Uchida T, Kariyone S, Friese P, Burstein S.A. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA. 86:1989;5953-5957.
47. Ford H.R, Hoffmann R.A, Tweardy D.J, Kispert P, Wang S, Simmons R.L. Evidence that production of interleukin 6 within the rejecting allograft coincides with cytotoxic T lymphocyte development. Transplantation. 51:1991;656-661.
48. Amemiya H, Suzuki S, Ota K, et al. A novel rescue drug, 15-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients. Transplantation. 49:1990;337-343.
49. Ohlman S, Gannedahl G, Tydén G, Tufveson G, Groth C.G. Treatment of renal transplant rejection with 15-deoxyspergualin - a dose finding study in man. Transplant Proc. 24:1992;318-320.
50. Nemoto K, Hayashi M, Abe F, Takita T, Takeuchi T. Effects of deoxyspergualin on hameatopoiesis: studies of murine haematopoietic progenitor cell and peripheral blood cell levels. J Antibiot. 42:1989;321-326.
51. Kerr P.G, Atkins R.C. The effects of deoxyspergualin on lymphocytes and monocytes in vivo and in vitro. Transplantation. 48:1989;1048-1052.
52. + T cells in CD2-mediated activation. J Exp Med. 172:1990;1419-1424.
53. Lorré K, Damme J.V, Verwilghen J, Baroja M.L, Ceuppens L.L. Il-6 is an accessory signal in the alternative CD2-mediated pathway of T cell activation. J Immunol. 144:1990;4681-4687.
54. Baroja M.L, Ceuppens J.L, Damme J.V, Billiau A. Cooperation between an anti-T cell (anti-CD28) monoclonal antibody and monocyte-produced Il-6 in the induction of T cell responsiveness to Il-2. J Immunol. 141:1988;1502-1507.
55. Nadeau K, Nadler S.G, Saulnier M, Tepper M.A, Walsh C.T. Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry. 33:1994;2561-2567.
56. Hansen L.K, Houchins J.P, O'Leary J.J. Differential regulation of Hsc70, Hsp90α and heat shock in human lymphocytes. Exp Cell Res. 192:1991;587-596.
57. Twomey B.M, McCallum S, Isenberg D.A, Latchman D.S. Elevation of heat shock protein synthesis and hsp gene transcription during monocyte to macrophage differentiation of U937 cells. Clin Exp Immunol. 93:1993;178-183.